Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M567Revenue (TTM) $M15.0Net Margin (%)-425.4Altman Z-Score30.6
Enterprise Value $M204EPS (TTM) $-0.5Operating Margin %-448.6Piotroski F-Score2
P/E(ttm)--Beneish M-Score-2.0Pre-tax Margin (%)-425.4Higher ROA y-yN
Price/Book1.610-y EBITDA Growth Rate %-25.6Quick Ratio36.1Cash flow > EarningsY
Price/Sales38.75-y EBITDA Growth Rate %-26.5Current Ratio36.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-15.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-15.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)-1,482.2Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ACHN is held by these investors:



ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FISHERMAN JASON SDirector 2016-12-22Buy10,000$3.964.8view
Fenton Mary KayCFO 2016-12-05Buy2,500$4.110.97view
Truitt JosephChief Commercial Officer 2016-12-02Buy3,500$4.062.22view
MANNING MARTHA EEVP, General Counsel 2016-12-02Buy2,500$4.091.47view
Deshpande MilindCEO 2016-12-02Buy2,500$4.062.22view
Barrish Joel CChief Scientific Officer 2016-12-02Buy2,500$4.062.22view
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-60.48view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-58.83view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-59.19view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.22-49.51view

Press Releases about ACHN :

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs May 04 2017 
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference May 02 2017 
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks Apr 22 2017 
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturn Apr 06 2017 
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pat Mar 21 2017 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 

More From Other Websites
Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx May 19 2017
Why Achillion Pharmaceuticals Stock Is Jumping 15% Today May 18 2017
Achillion: It Can't Get Any Worse…Or Can It? May 18 2017
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : May 11, 2017 May 11 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... May 10 2017
Achillion (ACHN) Reports Wider-than-Expected Loss in Q1 May 08 2017
Achillion reports 1Q loss May 04 2017
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs May 04 2017
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference May 02 2017
ETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017 Apr 25 2017
Why Achillion Pharmaceuticals Stock Sank on Monday Apr 25 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Apr 25 2017
Why Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today Apr 24 2017
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks... Apr 22 2017
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss Apr 20 2017
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal... Apr 06 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals Mar 31 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Mar 30 2017
Why Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report? Mar 28 2017
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative... Mar 21 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)